

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 2013240248 B2**

(54) Title  
**Delivery of packaged RNA to mammalian cells**

(51) International Patent Classification(s)  
**C12N 7/00** (2006.01)      **C12N 15/86** (2006.01)

(21) Application No: **2013240248**      (22) Date of Filing: **2013.03.15**

(87) WIPO No: **WO13/148302**

(30) Priority Data

(31) Number **61/615,687**      (32) Date **2012.03.26**      (33) Country **US**

(43) Publication Date: **2013.10.03**  
(44) Accepted Journal Date: **2018.12.20**

(71) Applicant(s)  
**The United States of America, as represented by the Secretary, Department of Health and Human Services**

(72) Inventor(s)  
**Kaczmarczyk, Stanislaw J.;Chatterjee, Deb K.**

(74) Agent / Attorney  
**Watermark Intellectual Property Pty Ltd, L 1 109 Burwood Rd, Hawthorn, VIC, 3122, AU**

(56) Related Art  
**US 2008/0118956 A1**  
**Piver E et al, "Mobilization of full-length Semliki Forest virus replicon by retrovirus particles", Journal of Virology, 2006, 80(19):9889-9895**  
**WO 2008/115199 A2**  
**Jurgens CK et al, "A novel self-replicating chimeric lentivirus-like particle", Journal of Virology, 2012, 86(1):246-261, Epub 19 October 2011**

**(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)**

**(19) World Intellectual Property Organization**  
International Bureau



WIPO | PCT



**(10) International Publication Number**

WO 2013/148302 A1

**(43) International Publication Date  
3 October 2013 (03.10.2013)**

**(51) International Patent Classification:**  
*C12N 7/00* (2006.01)      *C12N 15/86* (2006.01)

**(21) International Application Number:** PCT/US2013/031876

**(22) International Filing Date:** 15 March 2013 (15.03.2013)

**(25) Filing Language:** English

(29) Publication Language: English

01/015,087 26 March 2012 (26.03.2012) US

(71) Applicant: THE UNITED STATES OF AMERICA, as

(7) **Applicant:** THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT

represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF

DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF  
TECHNOLOGY TRANSFER, NATIONAL INSTITUTE

TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH [US/US]; 6011 Executive Boulevard, Suite 325, MSC 7660, Bethesda, MD 20892-7660 (US).


(72) **Inventors:** KACZMARCZYK, Stanislaw, J.; 1839 Country Run Way, Frederick, MD 21702 (US). CHATTERJEE, Deb, K.; 24 Beman Woods Court, Potomac, MD 20854 (US).

(74) **Agents:** CALDWELL, John, W. et al.; Woodcock Washburn LLP, Cira Centre, 12th Floor, 2929 Arch Street, Philadelphia, PA 19104-2891 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

**(54) Title: DELIVERY OF PACKAGED RNA TO MAMMALIAN CELLS**



**(57) Abstract:** Described herein are compositions relating to alphavirus-based virus-like particles (VLPs) and methods for making and using the described VLPs. The described compositions include VLPs and vectors and cells used to produce the VLPs. Also included are related methods to produce the VLPs, to transduce cells using the VLPs, and to produce a protein or polynucleotide of interest in a target cell using the VLPs. Also described are alphavirus-based replicons that allow for expression of proteins or polynucleotides of interest in a target cell without a cytopathic effect.

FIG. 11



**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

## DELIVERY OF PACKAGED RNA TO MAMMALIAN CELLS

## CROSS REFERENCE TO RELATED APPLICATIONS

**[0001]** This application claims the benefit of United States Provisional Application No. 61/615,687 filed March 26, 2012, which is hereby incorporated by reference in its entirety.

## TECHNICAL FIELD

**[0002]** The invention described herein relates to delivering and transcribing recombinant polynucleotides to mammalian cells using replication-defective virus-like particles.

## BACKGROUND

**[0003]** Alphaviruses belong to the group IV Togaviridae family of viruses. The alphaviruses are small, spherical, enveloped viruses with a genome of a single positive sense strand RNA. The total genome length ranges between 11,000 and 12,000 nucleotides, and has a 5' cap, and 3' poly-A tail. The four non-structural protein genes (NSP genes) are encoded in the 5' two-thirds of the genome, while the three structural proteins are translated from a subgenomic mRNA colinear with the 3' one-third of the genome.

**[0004]** There are two open reading frames (ORFs) in the alphavirus genome, non-structural and structural. The first includes NSP genes and encodes proteins (nsP1–nsP4) necessary for transcription and replication of viral RNA. The second encodes three structural proteins: the core nucleocapsid protein C, and the envelope proteins P62 and E1 that associate as a heterodimer. The viral membrane-anchored surface glycoproteins are responsible for receptor recognition and entry into target cells through membrane fusion.

**[0005]** The Sindbis (and VEEV) virus is an alphavirus whose genome comprises a positive mRNA strand of 11703 nucleotides. This virus infects a variety of vertebrate hosts. The genome of Sindbis virus encodes nonstructural (NS, replicon) and structural proteins (capsid and pH dependent fusogenic envelope) that are directly translated in the cytoplasm of the host cell. The alphaviruses also include Aura virus, Babanki virus, Barmah Forest virus, Bebaru virus, Cabassou virus, Chikungunya virus, Eastern equine encephalitis virus, Everglades virus, Fort Morgan virus, Getah virus, Highlands J virus, Kyzylagach virus, Mayaro virus, Me Tri virus, Middelburg virus, Mosso das Pedras virus, Mucambo virus, Ndumu virus, O'nyong-nyong virus, Pixuna virus, Rio Negro virus, Ross River virus, Salmon pancreas disease virus, Semliki Forest

virus, Southern elephant seal virus, Tonate virus, Trocara virus, Una virus, Venezuelan equine encephalitis virus, Western equine encephalitis virus, and Whataroa virus.

**[0006]** Infection of host cell with an alphavirus results in cytotoxicity culminating with apoptosis. This is mostly due to both: expression of alphavirus genomic RNA in large quantities triggering antiviral state in host cells and direct interaction of alphaviral non-structural proteins (NSP2 of SIN or NC of VEEV) with cellular mRNA synthesis or translational shut-off causing cytopathic effect (CPE) on host cell host cell. A natural Sindbis virus variant containing a point mutation in one of the nonstructural proteins, NSP2 (at position 726) demonstrated sustained and noncytopathic growth in infected cells although the viral titer recovered from infected cells was substantially reduced (Frolov, I. et al., J. Virol. 3845-65 (May, 1999)).

**[0007]** Alphaviruses are of interest to gene therapy researchers. Ross River virus, Sindbis virus, Semliki Forest virus (SFV), and Venezuelan equine encephalitis virus (VEEV) have all been used to develop vectors for gene delivery. Pseudotyped viruses may be formed by combining alphaviral envelopes glycoproteins and retroviral capsids. Alphaviral envelope glycoproteins pseudotyped retroviruses or lentiviruses are able to integrate the genes that they carry into the potential host cells. The pseudotyped alphaviruses are recognized and infected by the alphaviral envelope proteins E2 and E1. Stable integration of viral genes is mediated by retroviral interiors of these vectors.

**[0008]** There are limitations to the use of alphaviruses in the field of gene therapy due to their lack of specificity of targeting. However, through the introduction of variable antibody domains in a non-conserved loop in the structure of E2, specific populations of cells have been targeted. Furthermore, the use of whole alphaviruses for gene therapy is of limited efficacy both because several internal alphaviral proteins are involved in the induction of apoptosis upon infection and also because the alphaviral capsid mediates only the transient introduction of mRNA into host cells. Neither of these limitations extends to alphaviral envelope pseudotypes of retroviruses or lentiviruses.

## SUMMARY

**[0009]** One aspect of the description is a replication defective virus like particle (VLP) comprising:

- a. an alphavirus replicon isolated from a Sindbis virus or Venezuelan equine encephalitis virus comprising a recombinant polynucleotide

comprising a sequence encoding Sindbis virus or Venezuelan equine encephalitis virus nonstructural proteins (NSP) NSP1, NSP2, NSP3, and NSP4; and a retroviral packaging signal isolated from Rous sarcoma virus,

b. a retroviral gag protein encoded by a polynucleotide comprising a genomic sequence of a Rous sarcoma virus, and

c. a fusogenic envelope protein,

wherein the VLP does not contain an alphavirus structural protein gene.

The fusogenic envelope protein is selected from the group consisting of haemagglutinin, Rous sarcoma virus (RSV) fusion protein, an E protein of tick borne encephalitis virus and dengue fever virus, the E1 protein of SFV, baculovirus gp64, and Vesicular stomatitis (Indiana) virus-G (VSV-G) protein, preferably a glycoprotein, or fragment or derivative thereof, more preferably from a RNA virus or a retrovirus, or fragment or derivative thereof, most preferably VSV-G or EnvA, or an alteration of VSV-G. The VLP described herein may be capable of binding to a eukaryotic cell, preferably a human cell. The binding of the VLP may be specific to a target cell. The VLP described herein preferably replicates in the target cell. In some embodiments the VLP described herein is not cytopathic to the cell. The recombinant polynucleotide of the VLP may comprise a miRNA, shRNA or an antisense RNA, preferably a shRNA or antisense RNA that knocks down expression of a gene in the cell. The recombinant polynucleotide of the VLP may comprise an RNA encoding a protein that can be expressed by the cell.

**[0010]** Another embodiment of the description is a method of producing the VLP described herein, comprising the steps of co-transforming a eukaryotic cell with a first vector comprising a polynucleotide sequence encoding the alphavirus replicon, wherein the alphavirus replicon includes the polynucleotide of interest, a second vector comprising a polynucleotide sequence encoding the retroviral gag protein, and a third vector comprising a polynucleotide sequence encoding the fusogenic envelope protein; culturing the co-transformed cell under conditions suitable to cause each vector to produce its encoded product, thereby producing the VLP, and isolating the VLP from the cell, wherein neither the vectors nor the cell contain any alphavirus structural protein genes.

**[0011]** Another embodiment of the description is kit comprising a first vector comprising a polynucleotide sequence encoding an alphavirus replicon, wherein the alphavirus replicon includes the polynucleotide of interest; a second vector comprising a polynucleotide sequence encoding the retroviral gag protein; and a third vector comprising a polynucleotide sequence encoding the fusogenic envelope protein, such as VSV-G. In some embodiments, the vectors provided with the kits do not include alphavirus structural protein genes. Alternatively, in some embodiments one or more of the alphavirus replicon, retroviral gag protein and fusogenic envelope protein may be encoded by the same vector.

**[0012]** Another embodiment of the description is a method of expressing the recombinant polynucleotide in a eukaryotic cell comprising treating a cell with the VLP described herein.

**[0013]** Another embodiment of the description is a method of delivering the recombinant polynucleotide described herein to a subject, comprising administering to said subject the VLP described herein.

**[0014]** Another embodiment of the description is a method of treating or preventing a disease or a disorder in a subject, comprising administering to a subject the VLP described herein. Preferably, expression of the gene of interest supplements deficient expression of an endogenous gene by said subject.

**[0015]** Another embodiment of the description is a pharmaceutical composition comprising the VLP described herein.

**[0016]** Another embodiment of the description is a eukaryotic cell produced by treating the cell with a VLP described herein.

**[0017]** To produce VLPS of this sort several components may be produced by transfecting or nucleofecting one or more vectors encoding these components into a cell line for in vitro production. In some embodiments, these components are encoded by separate vectors to reduce the likelihood that the resulting VLP will be replication competent. For example, a multi-vector system may be used where one vector encodes the genetic material, such as an alphavirus-based RNA polynucleotide, to be packaged by the VLP; another encodes the structural proteins of the VLP, such a gag protein; and another vector encodes a fusion protein, such as VSV-G, to facilitate fusion of the VLP to the membrane of a target cell. The alphavirus-based RNA polynucleotide can be derived from any alphavirus. In some embodiments, the RNA polynucleotide is derived from Sindbis virus and encodes Sindbis virus nonstructural protein. In some embodiments, the RNA polynucleotide is derived from Venezuelan equine encephalitis virus (VEEV) and encodes VEEV nonstructural proteins. However, other alphavirus nonstructural proteins may suffice for the RNA construct described herein. Suitable alphaviruses include Aura virus, Babanki virus, Barmah Forest virus, Bebaru virus, Cabassou virus, Chikungunya virus, Eastern equine encephalitis virus, Everglades virus, Fort Morgan virus, Getah virus, Highlands J virus, Kyzylagach virus, Mayaro virus, Me Tri virus, Middelburg virus, Mosso das Pedras virus, Mucambo virus, Ndumu virus, O'nyong-nyong virus, Pixuna virus, Rio Negro virus, Ross River virus, Salmon pancreas disease virus, Semliki Forest virus, Southern elephant seal virus, Tonate virus, Trocara virus, Una virus, Venezuelan equine encephalitis virus, Western equine encephalitis virus, and Whataroa virus.

**[0018]** Also described herein are cells comprising the vectors described to produce VLPs. These cells may be used to produce the VLPs described herein by transcribing or expressing the polynucleotides of the vectors. For instance, a mammalian cell transfected with a

vector having a polynucleotide sequence encoding an alphavirus RNA construct having a gene or polynucleotide of interest and a packaging signal, a vector encoding a retroviral gag protein, and a vector encoding a viral fusion protein could produce a VLP having the expressed viral fusion protein on its surface with one or two copies of the encoded alphavirus RNA construct housed inside the VLP. Furthermore, because none of these vectors encode alphavirus structural proteins the possibility of creating an infectious virus is substantially reduced compared to systems that do include alphavirus structural proteins.

**[0019]** VLPs produced using the vectors and cells are also described herein. The VLPs described herein will have four general characteristics: they will comprise one or two RNA molecules encoding an alphavirus replicon, and optionally a protein of interest; they will have a viral core comprising a retroviral gag protein, or, in some embodiments, a gag fusion protein; they will have a surface protein to facilitate fusion with a cell, and they will not contain a polynucleotide that encodes an alphavirus structural protein.

**[0020]** The VLPs described herein may be produced in a variety of ways, as will be apparent to those skilled in the art based on the provided disclosure. The commonality to these various methods is the expression of the described vectors in a cell capable of expressing the necessary proteins (gag and a fusion protein) and producing the alphavirus-based RNA replicon.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0021]** Fig. 1 illustrates the elements of the three vectors exemplified herein. Fig. 1A shows the plasmid pCMV-Sin Rep-protein of interest-2 (POI-2), which is a Sindbis virus-based replicon. Fig. 1B shows the plasmid pGAG-protein of interest-1 (POI-1), which encodes a retroviral gag protein. Fig. 1C shows the plasmid pEnvelope, which encodes the viral fusion protein, such as VSV-G.

**[0022]** Fig. 2 schematically shows an example of a vector according to the description corresponding to the plasmid depicted in Fig. 1A. The DNA sequence of the vector is provided in the Sequence Listing, appended hereto.

**[0023]** Fig. 3 schematically represents how the transducing VLPs described herein are produced.

**[0024]** Fig. 4 depicts the results of three separate VLP transduction experiments. Fig. 4A shows cells transduced with a GFP-expressing Sindbis virus replicon packaged into VLPs obtained from supernatants collected from Baby Hamster Kidney (BHK)-21 cells transfected with all three plasmids; Fig. 4B shows the absence of GFP expression in cells incubated with cell supernatants collected from BHK-21 cells nucleofected with only the pCMV-Sin Rep-POI-2 and

pGAG-POI-1 plasmids in the absence of envelope protein. Fig. 4C shows transduction of human embryonic kidney (HEK293T) cells to demonstrate that the constructed VLPs can transduce human cells.

**[0025]** Fig. 5 shows that the VLPs described herein can successfully transduce cells following storage at 4 °C for 1 hour (A), 2 days (B), 4 days (C), and 8 days (D).

**[0026]** Fig. 6 shows the expression levels of *Gaussia* luciferase by cells transduced with VLPs having a VEEV replicon capable of expressing the *Gaussia* luciferase gene (Fig. 6A, condition 4). Conditions 1, 2, and 3 of Fig. 6A show expression of *Gaussia* luciferase by cells transduced with VEEV replicons having no exogenous gene (condition 1) or with a gene encoding GFP (conditions 2 and 3). Fig. 6B provides an illustration of the expression kinetics of the luciferase protein during the first 4 hours after transduction.

**[0027]** Fig. 7 illustrates the genetic process by the cre/lox system can be used to alter gene expression in a cell by delivering cre recombinase to a cell via transduction with a VLP having a VEEV replicon with the cre recombinase gene (Fig. 7A). The gene expression profile for a cell line engineered to express GFP in the absence of cre recombinase and RFP in the presence of cre recombinase is shown before and after (days 5, 6, and 7) transduction with a VLP carrying a replicon capable of expressing cre recombinase. Fig. 7B shows results of delivering functional cre recombinase (red cells) to cells engineered to express GFP in the absence of cre recombinase.

**[0028]** Fig. 8 depicts expression of GFP following transduction of BHK-21 cells, 293T cells, or NIH3T3 cells with VLPs having either a Sindbis virus or VEEV-based replicon capable of expressing GFP. 24 and 48 hour time points are shown for all samples.

**[0029]** Fig. 9 Illustrates functional packaging of non-coding RNA into VLPs. Cells transduced with VLPs containing: VEE-rep-GFP (encoding GFP) (Fig. 9A), VEE-Rep miGFP (encoding microRNA for GFP) (Fig. 9B), VEERep-GFP and VEERep miGFP (simultaneous transduction) (Fig. 9C), VEERep-GFP and VEERep miGFP (miRNA transduction occurred 4 hours prior to GFP transduction) (Fig. 9D), VEE-rep-Cre ( used in place of scrambled miRNA to demonstrate specificity of miRNA) (Fig. 9E), VEE-Rep-GFP and VEE-Rep -Cre (simultaneous transduction) (Fig. 9F), or VEERep-Cre, incubation of cells for 4 hr prior to transduction with VLPs containing VEE-Rep-GFP (Fig. 9G).

**[0030]** Fig. 10 shows a schematic representation of an alphavirus replicon having two different genes (encoding either HLA-DR1 or CD80) the expression of which can occur in the same cell (Fig. 10A). Images of cells expressing both proteins following transduction with a VLP having a replicon shown in Fig. 10A are provided in Fig. 10B, where HLA-DR1 expression

is visualized using immunospecific labeling with FITC (green) and CD80 is visualized with immunospecific labeling with phycoerythrin (red); a merged image is also shown to illustrate coexpression in the same cells.

**[0031]** Fig. 11 provides a schematic representation of pDest472-VEE-MCS.

**[0032]** Fig. 12 provides a schematic representation of pDest472-VEE.

#### DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

**[0033]** Various alphavirus-based expression vectors for transgene expression in target cells have been described (Xiong C., et al., 1989, *Science* 1188-91; and Bredenbeek P. et al., 1993, *J. Virol.* 6439-46). For safety considerations these expression systems usually comprise two plasmids. One plasmid contains the coding sequence of the viral replicon (i.e., non-structural proteins) and an internal promoter and transgene coding region, while the second plasmid encodes the viral structural genes. These plasmids are used to generate mRNA in vitro, which is then electroporated into host cells to generate one-round infectious virus particles. These viral particles are then used to infect target cells for transgene expression. These particles raise safety concerns, however, because recombination between the sequence elements encoding the non-structural and the structural viral elements can yield replication-competent alphavirus particles having the ability to mediate a significant cytopathic effect *in vivo*.

**[0034]** A possible solution to this problem is to use unrelated VLPs to deliver alphavirus replicons to the cytoplasm of mammalian cells where they can replicate autonomously and express genes of interest without any nuclear involvement. These VLPs can be produced using three vectors. The first vector comprises the coding sequence for the alphavirus replicon under the control of a mammalian promoter (e.g., CMV), a retroviral-specific RNA packaging signal, and a gene or polynucleotide of interest. The gene may express a protein with therapeutic or research applications, or a shRNA or other regulatory nucleic acid. The second vector comprises retroviral Gag. The third vector would provide the suitable envelope glycoprotein for infection of target cells.

**[0035]** Upon co-transfection into an appropriate packing cell line, RNA molecules transcribed from the cellular promoter present in the first vector will be packaged into VLPs produced from the second vector. These VLPs can deliver the alphavirus-based replicon to a target cell based on the envelope glycoprotein present in the VLPs. Once inside the cell, the host

translational machinery will translate the introduced alphavirus RNA and produce alphavirus replication proteins, which will in turn amplify the RNA and express the gene or polynucleotide of interest. Mutant replicons such as the one described above can greatly prolong the duration of expression with minimal impact on the host cell. Moreover, DNA encoding genes for alphavirus structural elements will be absent in the target cell, so the safety of the proposed system is greatly enhanced.

**[0036]** Described herein are compositions relating to VLPs and methods for making and using the described VLPs. The described compositions include VLPs, and vectors and cells used to produce the described VLPs. The related methods described herein relate to methods of producing the VLPs, methods of transducing cells using the VLPs, and methods of producing a protein or polynucleotide of interest in a target cell using the VLPs described herein. Also described are alphavirus-based replicons that allow for expression of proteins or polynucleotides of interest in a target cell without the risk of viral infection.

#### Definitions

**[0037]** When the terms “one,” “a,” or “an” are used in this disclosure, they mean “at least one” or “one or more,” unless otherwise indicated.

**[0038]** The term “fusogenic protein” as used herein is meant to refer to a protein that can induce the fusion of the plasma membrane derived envelope of the VLP to the membrane of the recipient cell.

**[0039]** The terms “express” and “produce” are used synonymously herein, and refer to the biosynthesis of a gene product. These terms encompass the transcription of a gene into RNA. These terms also encompass translation of RNA into one or more polypeptides, and further encompass all naturally occurring post-transcriptional and post-translational modifications. The expression or production of an antibody or antigen-binding fragment thereof may be within the cytoplasm of the cell, or into the extracellular milieu such as the growth medium of a cell culture.

**[0040]** “Polynucleotide,” synonymously referred to as “nucleic acid molecule,” “nucleotides” or “nucleic acids,” refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. “Polynucleotides” include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.

In addition, “polynucleotide” refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. “Polynucleotide” also embraces relatively short nucleic acid chains, often referred to as oligonucleotides.

**[0041]** “Replicon” as used herein refers to a polynucleotide having the genetic elements necessary to facilitate replication of its sequence and while also being capable of undergoing translation.

**[0042]** “Virus-like particle” (VLP), as used herein, refers to a structure resembling a virus particle. In preferred embodiments, a VLP contains at least one fusogenic protein displayed on the surface of the particle. A virus-like particle in accordance with the invention lacks all or part of the replicative components of the viral genome. Typically, a virus-like particle in accordance with the invention does not carry genetic information encoding for the proteins of the virus-like particle.

**[0042a]** Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.

### Vectors

**[0043]** Described herein are vectors for use in producing VLPs carrying an alphavirus-based replicon that does not encode alphavirus structural proteins. To produce VLPs of this sort, several components may be produced by transfecting or nucleofecting one or more vectors encoding these components into a cell line for in vitro production. In some embodiments, these components are encoded by separate vectors to reduce the likelihood that the resulting VLP will be replication competent. For example, a multi-plasmid system may be used where one plasmid encodes the genetic material, such as an RNA polynucleotide encoding Sindbis virus or VEEV nonstructural proteins, to be packaged by the VLP; another encodes the structural proteins of the VLP, such as gag; and another plasmid encodes a fusion protein, such as VSV-G, to facilitate fusion of the VLP to the membrane of a target cell.

**[0044]** The vectors encoding the genetic material to be packaged by a host cell can take a variety of forms, such as selectable or inducible plasmids, but generally have some common characteristics. For example, vectors encoding an RNA alphavirus-based replicon described

PAGE 10 TO FOLLOW

herein may include a promoter sequence, a retroviral packaging signal sequence, translation initiation sequences, nonstructural alphavirus proteins, a cloning site for inserting a gene or polynucleotide of interest, an inserted gene or polynucleotide of interest, a 3' untranslated region, and a poly-adenosine tail segment.

**[0045]** In some embodiments the described vectors include a promoter element that allows for segments of the vector to be transcribed by a host cell. In some embodiments the vector sequence may be transcribed into RNA to be packaged into a VLP. In most embodiments of the described vectors, the promoter sequence will be located upstream of all of the translatable elements included within the vector (see for example, Fig. 1(a) illustrating the location of the cytomegalovirus promoter “pCMV”). In some embodiments described herein the promoter sequence will be derived from a virus, such as cytomegalovirus (CMV), or simian virus 40 (SV40). Numerous other promoter sequences are well known to those skilled in the art and their use with the vectors described herein would be apparent based on the description provided.

**[0046]** In some embodiments the described vectors encoding the genetic material to be packaged by a host cell can include a polynucleotide sequence that encodes a retroviral packaging signal sequence (also known as a psi ( $\Psi$ ) element) to allow one or two copies of the RNA sequence transcribed from the vector to be packaged into a VLP particle formed in a host cell. Most, if not all, retroviruses have a packaging sequence of this nature, thus these sequences, and their incorporation into the described vectors, will be readily apparent to those skilled in the art. In some embodiments the vectors described herein include a polynucleotide sequence that encodes a retroviral packaging sequence derived from Rous sarcoma virus, Moloney murine leukemia virus, simian immunodeficiency virus (SIV), HIV, human T-lymphotropic virus, and the like. In a particular embodiment, the retroviral packaging sequence is derived from Rous sarcoma virus. Alternatively, the retroviral packaging sequence is derived from murine leukemia virus.

**[0047]** Another aspect of the vectors encoding the genetic material to be packaged by a host cell described herein are translation initiation sequences, which allow the RNA sequence encoded by the vector to be translated in a host cell. In some embodiments the described translation initiation sequences may be capable of allowing for expression of alphavirus-based nonstructural proteins, which can replicate the RNA sequence carried by the described VLPs once it is delivered to the host cell. In some embodiments, the described translation initiation sequences may be capable of allowing for expression of a gene of interest. In some embodiments the translation initiation sequence may allow for the gene of interest to be translated by host cell translation complexes. In some embodiments the translation initiation sequences described

herein may be derived from an alphavirus, such as Sindbis virus or VEEV. In other embodiments the translation initiation sequences may be derived from other genes, such as virus genes known to have translation initiation sequences capable of initiating translation of an RNA sequence by mammalian translation complexes. Alternatively, the translation initiation sequences may be derived from other genes, such as the native translation initiation sequence of the gene of interest inserted into the described alphavirus replicon. In some embodiments the translation initiation sequences described herein may be located at more than one location in the packaged RNA molecule, and thus may be encoded one or more times by the described vectors. For example, it may be desirable to translate the described Sindbis or VEEV nonstructural proteins separately from a gene of interest encoded by the package RNA molecule. In such an instance, both the polynucleotide(s) encoding the nonstructural proteins and the polynucleotide encoding the protein of interest will have separate translation initiation sequences located 5' of their position in the vector and packaged RNA. Based on this description, those skilled in the art will understand that a variety of translation initiation sequences capable of promoting the translation of RNA in a mammalian cell may be incorporated to the described VLP-packaged RNAs described herein.

**[0048]** The vectors encoding genetic material to be packaged by a host cell may also include polynucleotides that encode nonstructural alphavirus proteins, such as nonstructural proteins from Sindbis virus or VEEV. For example, in some embodiments the described vectors may include polynucleotides that encode one or more Sindbis virus nonstructural proteins. In some embodiments the described vectors may include polynucleotides that encode one or more VEEV nonstructural proteins. In some embodiments described vectors may include polynucleotides that encode the Sindbis virus or VEEV nonstructural protein NSP1. In some embodiments described vectors may include polynucleotides that encode the Sindbis virus or VEEV nonstructural protein NSP2. In some embodiments described vectors may include polynucleotides that encode the Sindbis virus or VEEV nonstructural protein NSP3. In some embodiments described vectors may include polynucleotides that encode the Sindbis virus or VEEV nonstructural protein NSP4. In some embodiments described vectors may include polynucleotides that encode the Sindbis virus or VEEV nonstructural proteins NSP1, NSP2, NSP3, and NSP4. In some embodiments the polynucleotide of the described vector that encodes the alphavirus nonstructural proteins will be derived from the corresponding genomic sequence of an alphavirus genome, such as that of Sindbis virus or VEEV. In some embodiments, the polynucleotides encoding the alphavirus nonstructural proteins are void of any polynucleotides

that encode the alphavirus structural proteins, regardless of whether the structural proteins are from the same or a different alphavirus than the nonstructural protein sequences present.

**[0049]** The vector described herein for incorporating genetic material to be packaged by a host cell may also contain a polynucleotide of interest that may be expressed in a host cell transduced by a VLP carrying the genetic material encoded by the vector. In some embodiments the described vectors may encode an RNA polynucleotide sequence to be packaged into a VLP, which can then be delivered to a host cell by VLP-mediated transduction of the cell. Once the RNA polynucleotide sequence has been delivered to the target cell a polynucleotide of interest encoded by the RNA may provide for expression of a protein of interest. Accordingly, the vectors described herein are designed to encode an RNA for packaging into a VLP that can express a gene of interest once inside a target cell. Therefore, in some embodiments the described vectors will include a polynucleotide sequence of interest. In some embodiments of the described vector, the polynucleotide sequence of interest may encode a protein of interest. For example, the polynucleotide sequence of interest may encode GFP in some embodiments and serve a detectable marker of viral transduction of a target cell. In another embodiment, the polynucleotide sequence of interest may encode a functional version of a protein endogenous to the target cell. In another embodiment, the polynucleotide sequence of interest may encode a functional version of a protein endogenous to the target subject. In another embodiment, the polynucleotide sequence of interest may encode a protein that is foreign to the target cell. In another embodiment, the polynucleotide sequence of interest may encode a protein that is foreign to the target subject. In some embodiments the polynucleotide sequence of interest may encode a protein capable of having a therapeutic effect on a target cell. In some embodiments the polynucleotide sequence of interest may encode a protein capable of having a therapeutic effect on a target subject. In an alternative embodiment the polynucleotide sequence of interest may serve as an interfering RNA molecule and function to regulate endogenous gene expression in a host cell. For example, in some embodiments the polynucleotide sequence of interest may comprise a sequence that provides for the formation of an RNA hairpin loop to initiate RNA interference. In addition, the polynucleotide of interest could be a positive or negative sense strand of RNA that can be transcribed by the RNA-dependent RNA polymerase complex formed by the alphavirus nonstructural proteins encoded by the packaged RNA molecule. Since this RNA-dependent RNA polymerase can transcribe RNA in the positive-sense and negative-sense directions, an interfering RNA sequence, such as a miRNA or shRNA, may be inserted into the packaged RNA replicon and can be designed to encode an interfering polynucleotide in either direction. Those of skill in the art will appreciate the therapeutic characteristic of this aspect of

the described transduction system, as it can allow for expression of selected proteins in a subject. In accordance with this aspect of the described vector, a cloning site having one or more restriction endonuclease sites may also be included in the vector, to facilitate insertion of a polynucleotide sequence of interest.

**[0050]** Another vector useful in the production of the VLPs described herein is a vector that encodes a virus structural protein. One such class of proteins is the retroviral group-specific antigen (gag) protein. The gag protein is the core structural protein of retroviruses and, in some instances, is capable of forming enveloped virus cores when expressed in eukaryotic cells. This property makes gag proteins particularly useful in the production of VLPs, because they can form the basic structural aspect of the particle and allow for packaging of RNA associated with a retroviral packaging signal sequence. Accordingly, described herein are vectors that include a polynucleotide that encodes a retroviral gag protein. In some embodiments, the described vectors include a polynucleotide that encodes a retroviral gag protein and a promoter polynucleotide sequence that allows for the gag gene sequence to be transcribed into mRNA by host cell RNA polymerase. In one embodiment, the promoter polynucleotide sequence is derived from a virus, such as SV40 or CMV. In some embodiments, the vector will further include a polynucleotide that encodes a protein of interest. Those skilled in the relevant art will understand that a polynucleotide sequence of a gag protein from any retrovirus may be used to produce the vectors and VLPs described herein. In some embodiments the polynucleotide sequence encoding the gag protein may be derived from Rous sarcoma virus. In some embodiments the polynucleotide sequence encoding the gag protein may be derived from murine leukemia virus. In some embodiments the polynucleotide sequence encoding the gag protein may be derived from SIV. In some embodiments the polynucleotide sequence encoding the gag protein may be derived from human T-lymphotropic virus.

**[0051]** Another vector useful in the production of the VLPs described herein is a vector that encodes a protein to mediate fusion between the VLP envelope and a host cell. A class of proteins suitable for this purpose is viral fusion proteins, which facilitate virus infection of cells by allowing an enveloped virus to fuse its membrane with that of a host cell. Many of viral fusion proteins also have known, or suspected, cellular receptor proteins that may allow for targeting of selected cell types, or in cases of more ubiquitous receptors, such as sialic acid for influenza virus, more generalized targeting may be desired. In some instances, viral fusion proteins work in conjunction with viral attachment proteins, ligands for cellular receptor, a receptor for a cell ligand, or accessory proteins, thus proteins of this sort may also be encoded by the described vectors, in addition to, or also by, the vector encoding a viral fusion protein.

Alternatively, in some embodiments a viral fusion protein from one virus may be encoded by the described vector along with a viral attachment protein of another virus, a ligand of a cellular receptor, a receptor of a cell ligand, or an accessory protein to facilitate, or direct, targeting of a VLP to a desired cell type. In some embodiments the viral fusion protein, viral attachment protein, ligand of a cellular receptor, receptor of a cell ligand, or accessory protein will be a type-I membrane protein, which will allow the extracellular domain of the protein to be oriented extracellularly when present on the cell surface. This will also allow the fusion protein to be correctly oriented following budding of a VLP from a packaging cell. Expression of such proteins in a cell will typically result in the cell surface being coated with the proteins, so that budding of a VLP from any part of the cell membrane will provide the VLP with some amount of the protein(s) on its surface. In some embodiments, the described vectors include a polynucleotide that encodes a viral fusion protein and a promoter polynucleotide sequence that allows for the fusion protein gene sequence to be translated into mRNA by host cell RNA polymerase. In one embodiment, the promoter polynucleotide sequence is derived from a virus, such as SV40 or CMV. In some embodiments, the described vectors include a polynucleotide that encodes a viral attachment protein and a promoter polynucleotide sequence that allows for the attachment protein gene sequence to be translated into mRNA by host cell RNA polymerase. In one embodiment, the promoter polynucleotide sequence is derived from a virus, such as SV40 or CMV. In some embodiments the vectors described herein include a polynucleotide that encodes a vesicular stomatitis virus G protein. In some embodiments the vectors described herein include a polynucleotide that encodes the influenza hemagglutinin protein. In some embodiments the vectors described herein include a polynucleotide that encodes the influenza neuraminidase protein. In some embodiments the vectors described herein include a polynucleotide that encodes the respiratory syncytial virus fusion protein. In some embodiments the vectors described herein include a polynucleotide that encodes the rotavirus VP7 protein. Other such fusion proteins will be apparent to those skilled in the art based on desired tropism or cell target of the associated virus.

#### Cells expressing the described vectors

**[0052]** Provided herein are cells comprising the vectors described to produce VLPs. These cells may be used to produce the VLPs described herein by transcribing or expressing the polynucleotides of the vectors. For instance, a mammalian cell transfected with a vector having a polynucleotide sequence encoding an alphavirus RNA construct having a gene or polynucleotide

of interest and a packaging signal, a vector encoding a retroviral gag protein, and a vector encoding a viral fusion protein could produce a VLP having the expressed viral fusion protein on its surface with one or two copies of the encoded alphavirus RNA construct housed inside the VLP. Furthermore, because none of these vectors encode alphavirus structural proteins the possibility of creating an infectious virus is substantially reduced compared to systems that do include alphavirus structural proteins.

**[0053]** The described cells may be any eukaryotic cell capable of transcribing, and where necessary (such as in the case of the gag and fusion proteins), translating the polynucleotides of the described vectors. The cells will likely be mammalian cells in many embodiments. For example, rodent cells, such as murine, hamster (CHO or BHK-21), or rat cells could be used to express the described vectors; canine cells, such as Madin Darby canine kidney cells, could be used to express the described vectors; primate cells, such as vero cells, could be used to express the described vectors; and human cells, such as HEK293T cells (human kidney), Hep-2 cells (human airway), Caco-2 (intestine), HeLa (epithelium), and other such cell lines known in the art, could be used to express the described vectors. In some embodiments the described cells can be transfected and selected, using standard transfection and selection methods known in the art, to stably comprise one or more of the described vectors.

**[0054]** In some embodiments the cell lines described herein will contain a vector comprising a polynucleotide sequence encoding an alphavirus replicon wherein the alphavirus replicon encodes a protein of interest, a vector comprising a polynucleotide sequence encoding a gag protein, and a vector comprising a polynucleotide sequence encoding a heterologous fusogenic envelope protein, wherein neither the vectors nor the cell contain a gene encoding an alphavirus structural protein. In some embodiments the alphavirus replicon may be derived from Sindbis virus or VEEV. In some embodiments the alphavirus replicon may have polynucleotide sequences that encode Sindbis virus or VEEV nonstructural proteins NSP1, NSP2, NSP3, NSP4, and a retroviral packaging signal. In some embodiments the retroviral packaging signal may be derived from either Rous sarcoma virus or murine leukemia virus. In some embodiments the polynucleotide sequence encoding the gag protein is derived from Rous sarcoma virus. In some embodiments the polynucleotide sequence encoding the heterologous fusogenic envelope protein encodes VSV-G.

#### Virus-like particles

**[0055]** VLPs produced using the vectors and cells are also described herein. The VLPs described herein will have four general characteristics: they will comprise one or two RNA

molecules encoding an alphavirus replicon, and optionally a protein of interest; they will have a viral core comprising a retroviral gag protein, or, in some embodiments, a gag fusion protein; they will have a surface protein to facilitate fusion with a cell, and they will not contain a polynucleotide that encodes an alphavirus structural protein.

**[0056]** The VLPs described herein will be useful in transducing cells in order to express a protein of interest therein. Accordingly, the described VLPs may incorporate one or two alphavirus-based RNA polynucleotides capable of encoding a protein of interest. To facilitate translation of the RNA sequence some embodiments of the described packaged RNA may include translation initiation sequences as described herein. In some embodiments the RNA sequence incorporated into the VLP will include a retroviral packaging sequence that will facilitate inclusion of the RNA into a forming VLP. In some embodiments the retroviral packaging sequence is derived from Rous sarcoma virus, Moloney murine leukemia virus, simian immunodeficiency virus (SIV), HIV, human T-lymphotropic virus, and the like. In a particular embodiment, the retroviral packaging sequence is derived from Rous sarcoma virus. Alternatively, the retroviral packaging sequence may be derived from murine leukemia virus. In addition, the RNA sequences included in the VLP may be capable of encoding nonstructural alphavirus proteins. For example, in some embodiments the packaged RNA may encode one or more Sindbis virus or VEEV nonstructural proteins. In some embodiments the packaged RNA may encode the Sindbis virus or VEEV nonstructural protein NSP1. In some embodiments the packaged RNA may encode the Sindbis virus or VEEV nonstructural protein NSP2. In some embodiments the packaged RNA may encode the Sindbis virus or VEEV nonstructural protein NSP3. In some embodiments the packaged RNA may encode the Sindbis virus or VEEV nonstructural protein NSP4. In some embodiments the packaged RNA may encode the Sindbis virus or VEEV nonstructural proteins NSP1, NSP2, NSP3, and NSP4. The packaged RNA may also include the polynucleotide sequence of a protein of interest. For example, the polynucleotide sequence of interest may encode GFP in some embodiments and serve a detectable marker of viral transduction of a target cell. In another embodiment, the polynucleotide sequence of interest may encode a functional version of a protein endogenous to the target cell. In another embodiment, the polynucleotide sequence of interest may encode a functional version of a protein endogenous to the target subject. In another embodiment, the polynucleotide sequence of interest may encode a protein that is foreign to the target cell. In another embodiment, the polynucleotide sequence of interest may encode a protein that is foreign to the target subject. In some embodiments the polynucleotide sequence of interest may encode a protein capable of having a therapeutic effect on a target cell. In some embodiments the polynucleotide sequence of

interest may encode a protein capable of having a therapeutic effect on a target subject. Those of skill in the art will appreciate the therapeutic characteristic of this aspect of the described VLPs, as they can allow for expression of selected proteins in a cell or subject.

**[0057]** The described VLPs may also comprise a viral gag protein to provide a viral core structure to the particle. The gag protein is the core structural protein of retroviruses and, in some instances, is capable of forming enveloped virus cores when expressed in eukaryotic cells. This property makes gag proteins particularly useful in the production of VLPs, because they can form the basic structural aspect of the particle and allow for packaging of RNA associated with a retroviral packaging signal sequence. Those skilled in the relevant art will understand that a gag protein from any retrovirus may be used to produce the vectors and VLPs described herein. In some embodiments the gag protein may be derived from Rous sarcoma virus. In some embodiments the gag protein may be derived from murine leukemia virus. In alternative embodiments the gag protein may be derived from SIV, HIV, human T-lymphotropic virus, or similar retrovirus.

**[0058]** Another component of the VLPs described herein is a protein to mediate fusion between the VLP envelope and a host cell. A class of proteins suitable for this purpose is viral fusion proteins, which facilitate virus infection of cells by allowing an enveloped virus to fuse its membrane with that of a host cell. Many of viral fusion proteins also have known, or suspected, cellular receptor proteins that may allow for targeting of selected cell types, or in cases of more ubiquitous receptors, such as sialic acid for influenza virus, more generalized targeting may be achieved. In some instances, viral fusion proteins may work in conjunction with viral attachment proteins, ligands of cellular receptors, receptors of cellular ligands, or accessory proteins, thus proteins of this sort may also be present on the VLP surface in addition to a viral fusion protein. Alternatively, in some embodiments the described VLPs may have a viral fusion protein from one virus and a viral attachment protein of another virus, a ligand of a cellular receptor, a receptor of a cellular ligand, or an accessory protein to facilitate, or direct, targeting of a VLP to a desired cell type. Similarly, the described VLPs may be produced to have more than one fusion protein in the VLP envelope, as this may facilitate fusion to a select variety of cell types. In some embodiments the VLP surface protein(s) will be a type-I membrane protein, which will allow the extracellular domain of the protein to be oriented extracellularly when present on the cell surface. This will also allow the fusion protein to be correctly oriented following budding of a VLP from a packaging cell. Expression of such proteins in a cell will typically result in the cell surface being coated with the proteins, so that budding of a VLP from any part of the cell membrane will provide the VLP with some amount of the fusion protein on its surface. In some

embodiments the VLPs described herein include a vesicular stomatitis virus G protein (VSV-G) to mediate cell fusion. In some embodiments the VLPs described herein include an influenza hemagglutinin protein to mediate cell fusion. In some embodiments the VLPs described herein include an influenza neuraminidase protein to facilitate cell fusion. In some embodiments the VLPs described herein include respiratory syncytial virus fusion protein. In some embodiments the VLPs described herein include the rotavirus VP7 protein. Other such fusion proteins will be apparent to those skilled in the art based on desired tropism or cell target of the associated virus.

**[0059]** The VLPs described herein may comprise an alphavirus replicon, wherein the alphavirus replicon includes a polynucleotide of interest or encodes a protein of interest, retroviral gag protein, and heterologous fusogenic envelope protein; wherein the VLP does not contain an alphavirus structural protein gene. In some embodiments the alphavirus replicon of the VLP is derived from Sindbis virus or VEEV. For example, the VLPs described herein may have an alphavirus replicon encoding Sindbis virus or VEEV nonstructural proteins NSP1, NSP2, NSP3, and NSP4. In some embodiments the retroviral packaging signal associated with the packaged RNA in the described VLPs is derived from either Rous sarcoma virus or murine leukemia virus. Based on this description, those skilled in the art will readily understand that the described VLPs may be modified to incorporate aspects of viruses that may facilitate VLP stability, RNA packaging, or cell entry. Such modifications should be understood to be within the scope of the disclosures provided herein.

#### Methods of producing the described VLPs

**[0060]** The VLPs described herein may be produced in a variety of ways, as will be apparent to those skilled in the art based on the provided disclosure. The commonality to these various methods is the expression of the described vectors in a cell capable of expressing the necessary proteins (gag and a fusion protein) and producing the alphavirus-based RNA replicon. Accordingly, a method of producing a VLP described herein may include co-transforming, transfecting, or nucleofecting a eukaryotic cell with a vector comprising a polynucleotide sequence encoding an alphavirus replicon, wherein the alphavirus replicon includes a polynucleotide of interest or encodes a protein of interest; a vector comprising a polynucleotide sequence encoding a retroviral gag protein; and a vector comprising a polynucleotide sequence encoding a heterologous fusogenic envelope protein; and culturing the co-transformed cell under conditions suitable to cause each vector to produce its encoded product, thereby producing a virus-like particle. In some embodiments the polynucleotide sequence encoding the alphavirus replicon may be derived from Sindbis virus or VEEV. In some embodiments the alphavirus

replicon may have polynucleotide sequences that encode Sindbis virus or VEEV nonstructural proteins NSP1, NSP2, NSP3, NSP4, and a retroviral packaging signal. In some embodiments the retroviral packaging signal may be derived from either Rous sarcoma virus or murine leukemia virus. In some embodiments the polynucleotide sequence encoding the gag protein is derived from Rous sarcoma virus. In some embodiments the polynucleotide sequence encoding the heterologous fusogenic envelope protein encodes VSV-G.

#### Compositions and methods of administration

**[0061]** Described herein are compositions comprising at least one described VLP and a pharmaceutically acceptable carrier. Such compositions are useful, for example, for administration to subjects in need of expression of an exogenous protein or increased expression of a protein normally found in those of the same species as the subject. The compositions may be formulated as any of various preparations that are known and suitable in the art, including those described and exemplified herein. In some embodiments, the compositions are aqueous formulations. Aqueous solutions may be prepared by admixing the VLPs in water or suitable physiologic buffer, and optionally adding suitable colorants, flavors, preservatives, stabilizing and thickening agents and the like as desired. Aqueous suspensions may also be made by dispersing the VLPs in water or physiologic buffer with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

**[0062]** The compositions may be formulated for injection into a subject. For injection, the compositions described may be formulated in aqueous solutions such as water or in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. The solution may contain one or more formulatory agents such as suspending, stabilizing or dispersing agents. Injection formulations may also be prepared as solid form preparations which are intended to be converted, shortly before use, to liquid form preparations suitable for injection, for example, by constitution with a suitable vehicle, such as sterile water, saline solution, or alcohol, before use.

**[0063]** The compositions may be formulated for aerosolized delivery to a subject. For aerosol delivery, the compositions described may be formulated in aqueous solutions such as water or in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. The solution may contain one or more formulatory agents such as suspending, stabilizing or dispersing agents.

**[0064]** The compositions may be formulated in sustained release vehicles or depot preparations. Such long-acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compositions may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. Liposomes and emulsions are well-known examples of delivery vehicles suitable for use as carriers for hydrophobic drugs.

**[0065]** The following examples are provided for illustrative purposes and are meant to enhance, not limit, the preceding disclosure.

#### **EXAMPLE 1 – Production of an Alphavirus-based Gene Expression System**

**[0066]** An alphavirus gene expression system was designed to allow for VLP-mediated delivery an exogenous gene of interest (GOI) or protein of interest (POI) to a target cell with low risk of causing cytopathic viral infection. The expression system was designed using three vectors, which can be expressed in a packaging cell line to produce a transducing VLP. One vector codes for the alphavirus-based expression construct, another vector codes for a retroviral gag protein to facilitate VLP formation, and a third vector codes for a fusion protein to mediate VLP fusion to the host cell. In addition, the system was constructed to work without the need for alphavirus structural proteins being present.

**[0067]** To accomplish this, an alphavirus-based DNA plasmid was produced having a cytomegalovirus promoter (CMV); followed by a retroviral packaging signal of respective retroviral packaging protein GAG; followed by a Sindbis or VEE virus genes encoding nonstructural proteins NSP1, NSP2, NSP3, and NSP4; and finally, one or more subgenomic promoter (SGP; a promoter for virus-encoded RNA-dependent RNA polymerase, resulting in the formation of mRNA) to drive expression of a gene of interest (GOI), consisting of a recombinant polynucleotide, and inserted into a multiple cloning site; a 3' untranslated region (URT); and a polyA tail. Fig. 2 shows an example of such an alphavirus-based DNA plasmid. In another version of this expression vector, the retroviral packaging signal (GAG) is omitted.

**[0068]** Another plasmid was constructed to encode a retroviral gag protein and a second, optional protein of interest (POI). A third plasmid was constructed to provide expression of a VSV-G viral fusion protein. A schematic of an embodiment of these plasmids is provided in Fig. 1A-1C, respectively. Fig. 1A shows pCMV-Sin Rep-POI-2, Fig. 1B shows pGAG-POI-1, and Fig. 1C shows pEnv for VSV-G.

**[0069]** Once constructed the plasmids were tested for the ability to produce VLPs carrying a Sindbis virus replicon having a gene of interest. For these experiments, green fluorescent protein (GFP) was used as the gene of interest in order to facilitate detection of delivery and intracellular expression of the gene. To produce VLPs, each of the three plasmids described above were transfected into baby hamster kidney (BHK-21) cells using a standard nucleofection procedure with an Amaxa system according to manufacturer instructions (Lonza) (Fig. 3).

**[0070]** Briefly, the BHK-21 cells at  $3 \times 10^6$  were re-suspended in 100  $\mu$ l nucleofection solution L (Amaxa) and transferred to tube containing 4.5  $\mu$ g of plasmid coding for GAG, 3  $\mu$ g plasmid coding for VSV-G glycoprotein and 100 nanograms of plasmid coding for Sindbis alphavirus replicon or 2.5 micrograms for VEE replicon (in total volume of 10  $\mu$ l). The mixture of cells and plasmids was transferred to nucleofection cuvette and nucleofected using Amaxa nucleofector II apparatus using settings for BHK-21. The nucleofected cells were re-suspended in 500  $\mu$ l of completed culture medium and transferred to tissue culture plate containing culture medium solution and incubated at 37°C for period of 72-96 hr or for 72 hr at 32°C. After this time supernatants consisting of VLPs and encapsidated alphavirus replicon was clarified by centrifugation at 3000 RPM/10 min at 4°C, filtered by 0.45 um filter and exposed to 10 units of DNase I (turbo<sup>TM</sup>-DNase (Ambion)) for 30 min at RT. Processed VLPs were stored at 4°C or frozen on dry ice and transferred to -80°C. As a negative control (fusion-defective VLPs), BHK-21 cells were also nucleofected with only the pCMV-Sin Rep-POI-2 or VEEV-Rep-POI and pGAG-POI-1 plasmids, but not the pEnvelope plasmid encoding VSV-G. Following transfection, the cells were incubated for 48–72 hours in tissue culture medium under normal growth conditions to allow for plasmid-driven production of VLPs. Once the transfected cells were finished incubating, the tissue culture supernatant, which should contain any produced VLPs, was collected. The collected cell supernatants were then added to cultured BHK-21 cells to determine if the cells could be successfully transduced with GFP. As shown in Fig. 4, cell supernatants collected from BHK-21 cells transfected with all three plasmids resulted in robust GFP expression when exposed to untransfected BHK-21 cells (Fig. 4A). Conversely, no GFP expression was observed for untransfected BHK-21 cells incubated with cell supernatants collected from BHK-21 cells transfected with only the pCMV-Sin Rep-POI-2 and pGAG-POI-1 plasmids (Fig. 4B). Similar experiments were also conducted using human embryonic kidney (HEK293T) cells to demonstrate that the constructed VLPs could transduce human cells (Fig. 4C). Furthermore, the constructed VLPs can also be stored at 4 °C for at least 30 days without losing the ability to transduce cells (Fig. 5A-5D).

**[0071]** Experiments were also conducted to assess the ability of VEEV-based alpha virus replicon to express protein in cells. For these studies BHK-21 cells were transduced with VLPs having a *Gaussia* luciferase gene inserted into a VEEV replicon. Following transduction, cell supernatants monitored for expression of luciferase protein. As shown in Fig. 6, high amounts of luciferase were detected in the supernatants of cells transduced with the VEEV replicon having the *Gaussia* luciferase gene (Fig. 6A, condition 4), relative to control VEEV replicons without an exogenous gene (condition 1), or with a gene encoding GFP (conditions 2 and 3). Additionally, expression of the luciferase protein increased rapidly after transduction (Fig. 6B). Similar results were also observed in the context of delivering functional cre recombinase (red cells) to cells engineered to express GFP in the absence of cre recombinase (Fig. 7B).

**[0072]** Cells were transduced in parallel with either Sindbis-based VLPs encoding GFP or VEEV-based VLPs encoding GFP. As shown in Fig. 8, both alphavirus-based VLPs caused robust GFP expression, while the cells transduced with VEEV-based VLPs were observed to have the higher expression levels (Fig. 8).

## **EXAMPLE 2 – miRNA Expressed by a VEE Alphavirus Replicon Inhibits Protein Production**

**[0073]** Experiments were conducted to assess whether an alphavirus replicon encoding an miRNA sequence could inhibit protein production. To assess this, BHK-21 cells were transduced with a VLP replicon encoding GFP, miRNA specific for GFP, or cre recombinase (Fig. 9). (See the vectors shown in Figs. 11 and 12, and SEQ ID NO:1 in Table 1, below.) GFP expression was noticeable reduced when cells were first transduced with a replicon encoding miRNA for GFP and then subsequently transduced with a replicon encoding GFP (4 hours after the intial transduction), as compared to cells transduced with only a replicon encoding GFP (compare Fig. 9A with Fig. 9D). Conversely, when cells were first transduced with a replicon encoding cre recombinase and then subsequently transduced with a replicon encoding GFP (4 hours after the initial transduction), no significant reduction in GFP expression was apparent (Fig. 9G).

## **EXAMPLE 3 – Expression of Multiple Proteins in Target Cells Transduced with VEE VLPs**

**[0074]** To assess whether an alphavirus replicon can express two separate proteins in the same cell, experiments were performed using a VEE replicon having HLA-DR1 under the control of one subgenomic promoter and CD80 under a another subgenomic promotor (Fig. 10A). Following production of VLPs having the described VEE replicon, cells were transduced and examined for expression of both proteins. As shown in Fig. 10B, transduced cells were able to express both proteins (immunolabeled HLA-DR1 is shown in green (FITC) and CD80 shown in red (phycoerythrin)).

Table 1: SEQ ID NO: 1

1 gacggatcg gagatctccc gatcccstat ggtgcactct cagtaatac tgctctgatg  
 61 ccgcatagtt aagccagtt ctgccccctg ctttgtgtt ggaggtcgct gagtagtgcg  
 121 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatt aagaatctgc  
 181 ttagggttag gcgtttcg cgtctcgat atgtacgggc cagatatacg cggtgacatt  
 241 gattattgac tagttattaa tagtaatcaa ttacggggc attagttcat agccatata  
 301 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc  
 361 cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc  
 421 attgacgtca atgggtggag tatttacggt aaactgccc cttggcagta catcaagtgt  
 481 atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt  
 541 atgcccagta catgacctt tggacttcc ctacttggca gtacatctac gtattagtca  
 601 tcgctattac catggtgatg cggtttggc agtacatcaa tggcgtgaa tagcggtttg  
 661 actcacgggg atttccaagt ctccacccca ttgacgtcaa tggagtttggcacc  
 721 aaaatcaacg gactttcca aaatgtcgta acaactccgc cccattgacg caaatggcg  
 781 gtaggcgtgt acgggtggag gtctatataa gcagagctcg tatggacata ttgtcgtag  
 841 aacgcggcta caattaatac ataaccttatacatacatacatacatacatacatacatacatac  
 901 atagattgac ggcgttagtac acactattga atcaaacagc cgaccaatttgc cactaccatc  
 961 acaatggaga agccagtagt aaacgttagac gtagacccccc agagtcgtt tgcgtgca  
 1021 ctgcaaaaaaa gttcccgca atttgaggta gtagcacagc aggtcactcc aaatgaccat  
 1081 gctaattgcca gaggatttc gcatctggcc agtaaactaa tcgagctgaa ggttcctacc  
 1141 acagcgcacg tcttggacat aggcagcgc cccgctcgta gaatgtttc cgagcaccag  
 1201 tatttcattgtg tctggccat gctgtgttcca gaagacccgg accgcattgt gaaatacgcc  
 1261 agtaaacttgg cggaaaaaagc gtgcaagatt acaaaacaaga acttgcattgt gaaagattaa  
 1321 gatctccggc cctgtacttgc tacggccgtat gctgaaacac catcgctctg ctttcacaac  
 1381 gatgttacat gcaacatgcg tgccgaaat tccgtcatgc aggacgtgt tatcaacgc  
 1441 cccggaaacta tctatcatca ggctatgaaa ggcgtcgccg ccctgtactg gattggcttc  
 1501 gacaccaccc agttcatgtt ctcggctatg gcagggtcgat accctgcgtt caacaccaac  
 1561 tggcccgacg agaaagtcct tgaagcgcgt aacatggac tttgcagcac aaagctgagt  
 1621 gaaggtagga caggaaaatt gtcgataatg aggaagaagg agttgaagcc cgggtcgcgg  
 1681 gtttatttct ccgttaggatc gacactttat ccagaacaca gagccagctt gcagagctgg  
 1741 catctccat cgggtgttcca cttgaatggaa aagcgtcgat acacttgcgc ctgtgatata  
 1801 gtggtagtt gcaaggctt cgtgtgttgc aaaaatccca tcagttccgg gatcacgggaa  
 1861 gaaaccgtgg gatacgcggt tacacacaat agcggggct tttgtatgc caaagttact  
 1921 gacacagtaa aaggagaacg ggtatcggtt cctgtgtgca cgtacatccc ggccaccata  
 1981 tgcgatcaga tgactggat aatggccacg gatataatcac ctgacgtgc acaaaaaactt  
 2041 ctgggtggc tcaaccacgc aattgtcatt aacggtagga ctaacaggaa caccaacacc  
 2101 atgcaaaaattt accttctgcc gatcatagca caagggttca gcaatgggc taaggagcgc  
 2161 aaggatgatc ttgataacga gaaaatgctg ggtacttagag aacgcacgt tacgtatggc  
 2221 tgcttgggg cggttcgcac taagaaagta cattcggtt atcgccacc tggacgc  
 2281 acctgcgtaa aagtcccacgc ctcttttagc gctttccca tgcgtccgt atggacgc  
 2341 tctttggccca tgcgtgttgc gcaaggatgtt aacttgcgtat tgcaacccaa gaaggaggaa  
 2401 aaactgcgtc aggtctcgaa ggaatttagtc atggaggccca aggctgttt tgaggatgt  
 2461 caggaggaag ccagagcggc gaaagctccga gaagcacttc caccattagt ggcagacaaa  
 2521 ggcacgcggc cagccgcaga agttgtcgat gaaagtggagg ggctccaggc ggacatcgaa  
 2581 gcaaggatgtt tgcgtgttgc gcaaggatgtt aacttgcgtat tgcaacccaa gaaggaggaa  
 2641 atgatcgac agtataatcgat tgcgtgttgc aacttgcgtat tgaagatgc caaactcgca  
 2701 ccagcgcacc cgcttagcaga tcaggatgtt atcataacac actccggaa atcaggaaagg  
 2761 tacggcgtcg aaccatacga cgctaaatgtt ctgtatgcgc caggaggatgc cgtaccatgg  
 2821 ccagaatttcc tagactgttgc tgagagcgc acgttagtgc acaacaaaag agagttgt  
 2881 aaccgcacaaat tataaccat tgcgtgttgc gggccggccca agaatacaga agaggaggaa  
 2941 tacaagggtt caaaggccaga gcttgcagaa acagagtcgt tggttgcgt ggacaagaagg  
 3001 ctggcgttca agaaggaaaga agcctcaggat ctggcgttgc cgggagaact gaccaaccct  
 3061 ccctatcatg agcttagctt ggaggactg aagacccgc ctgcgtccc gtacaaggc  
 3121 gaaacaatag gatgtatagg cacacgggg tcggccatgtt cagctattat caagtcaact  
 3181 gtcacggcac gagatcttgc taccacgcgaa aagaaagaaa attgtcgca aattgaggcc  
 3241 gacgtgttca gactggggg tttgcgttgcgtt acgtcgaaaga ctagatgc gtttatgt  
 3301 aacggatgccc acaaaggccgtt agaagtgcgt tgcgttgcgt aacgcgttgcgttgc  
 3361 ggagcactac ttgccttgcgt tgcgttgcgttgc aagggccgc aagaaatgtt actatgc  
 3421 gacccatgc aatgcggattt cttcaacatgc atgcactaa agtacattt caatcaccct

3481 gaaaaagaca tatgcaccaa gacattctac aagtatatct cccggcggt cacacagcca  
 3541 gttacagcta ttgtatcgac actgcattac gatggaaaga taaaaaccac gaacccgtgc  
 3601 aagaagaaca tggaaatcga tattacaggg gccacaaagc cgaagccagg ggatatcatc  
 3661 ctgacatgtt tcccggggtg ggttaagcaa ttgcaaattcg actatcccg acatgaagta  
 3721 atgacagccg cggcctcaca agggctaacc agaaaaggag tttatccgt ccggcaaaaa  
 3781 gtcaatgaaa acccaactgtc cgcgatcaca tcagagcatg tgaacgtt gtcacccgc  
 3841 actgaggaca ggctagtg gaaaaacctg cagggcgacc catggattaa gcagcccact  
 3901 aacataccta aaggaaactt tcaggctact atagaggact gggaaagctga acacaaggga  
 3961 ataattgctg caataaacag ccccaactccc cgtgccaatc cggtcagctg caagaccaac  
 4021 gtttgctggg cggaaagcatt ggaaccgata ctggccacgg ccggtatcgt acttaccgg  
 4081 tgccagtgga gcgaaactgtt cccacagttt gcggatgaca aaccacattc ggccatttac  
 4141 gccttagacg taatttgcatttttgc ggcattggact tgacaagcg actgttttct  
 4201 aaacagagca tcccaactaac gtaccatccc gccgatttag cgaggccgg agctcattgg  
 4261 gacaacagcc caggaacccg caagtatggg tacgatcag ccattccgc cgaactctcc  
 4321 cgtagatttc cgggttcca gctagtgaa aagggcacac aacttgattt gcagacgggg  
 4381 agaaccagag ttatctctgc acagcataac ctggccgg tgaaccgcaa tcttcctc  
 4441 gccttagtcc cggagttacaa ggagaagcaa cccggccgg taaaaaattt cttaaccag  
 4501 ttcaaacacc actcgtact tttgttatca gaggaaaaaa ttgaagctcc cgttaagaga  
 4561 atcgaatggc tggcccgat tggcatagcc ggtgcagata agaactacaa cctggcttc  
 4621 gggttccgc cgcaggcactg gtacgacccgt gtgttcatca acattggaa taaatacaga  
 4681 aaccaccact ttcagcgtg cgaagaccat gcccgcaccc taaaaccct ttccgcgttgc  
 4741 gcccgaatt gccttaaccc aggaggcacc ctctgttgc agtccatgg ctacccgcac  
 4801 cgcaacagtg aggacgttagt caccgtt gccagaaagt ttgtcagggt gtctgcagcg  
 4861 agaccagatt gtgtctcaag caatacagaa atgtacactg ttttccgaca actagacaaac  
 4921 agccgtacac ggcaattcac cccgcaccat ctgaaattgc tgatttcgtc cgttatgag  
 4981 ggtacaagag atggagttgg agccgcgcg tcataccgca cccaaaggaa gaatattgct  
 5041 gactgtcaag aggaagcagt ttttgcgttcaac gccaatccgc tggtagacc aggcgaaggaa  
 5101 gtctgcgttcaac gccaatccgc accagtttta ccgatttcac cacggagaca  
 5161 ggcacccgaa gaatgactgt gtcccttaga aagaaagtga tccacccgtt cggccctgtat  
 5221 ttccggaaaccccaaggc agaaggcttcaac aatttgcataaaaaccccta ccatgcgttgc  
 5281 gcagacttag taaatgaaca taacatcaag tctgtcgcca ttccactgtt atctacaggc  
 5341 atttacgcac ccggaaaaga ccgccttgcgaa gtatcactt actgcgttgc aaccgcgtt  
 5401 gacagaactg acgcggacgt aaccatctt tccctggata agaagtggaa ggaaagaatc  
 5461 gacgcggcac tccaaacttgg  
 5521 gacgtatgtt tagtatggat tcacccatccac agttgttgc agggagaaa gggattcagt  
 5581 actacaaaag gaaaattgtt ttctgttccgc gacccatccac aattccatca agcagcaaaa  
 5641 gacatggcg agataaagggt cctgttccctt aatgaccagg aaagtaatga acaactgtgt  
 5701 gcctacatat tgggtgagac catggaaagca atccgcgaaa agtccgttgc cggccatata  
 5761 ccgtcgatccgc gcccggccaa aacgttgcg tgccttgc tttatccgttgc gacgcccgg  
 5821 aggggtccaca gacttagaa caataacgtt aaagaagtta cgtatgttgc ctccacccccc  
 5881 ttccctaagc acaaaaattaa gaatgttgc aaggttgc tttatccgttgc gacgaaaagt agtccgttgc  
 5941 aatccgcaca ctcccgatccgc tttatccgttgc gacgcccggccatata  
 6001 accgcgttgc ttcacccatccac agttgttgc agggagggcc cccgaagttt tagcgttgc  
 6061 acagctgttgc acacccgttgc tgatgttgc gacatcttgc tggatatggaa tgacagtg  
 6121 gaaggcttgc ttttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc  
 6181 tgggtcgatccgc gacttagtttccgc actagagata gtagaccgaa ggcaggtgg ttttgc  
 6241 gttcatgttgc tccaaagggcc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc  
 6301 ctggcggccg caaaaaaaa gcccacttgc cccgcggccgca atagcttgc ttttgc ttttgc  
 6361 ctcttttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc  
 6421 caggcggccg ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc  
 6481 ttttgc  
 6541 ttttgc  
 6601 ttttgc  
 6661 ggggttaggtt ggttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc  
 6721 gttctgcaga accagtttac agaaccggacc ttggagcgca atgttgc ttttgc ttttgc  
 6781 gccccgggttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc  
 6841 accgaagccca acaaaaaggtag gtaccgttgc ttttgc ttttgc ttttgc ttttgc ttttgc  
 6901 actgagccgac tactgttgc actacgttgc ttttgc ttttgc ttttgc ttttgc ttttgc  
 6961 tataagatca cttatccgaa accatgttgc ttttgc ttttgc ttttgc ttttgc ttttgc  
 7021 ccacagttcg ctgttagctgt ctgttgc ttttgc ttttgc ttttgc ttttgc ttttgc  
 7081 ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc

7141 tgcctggata ctgcaacctt ctgccccgt aagcttagaa gttacccgaa aaaacatgag  
 7201 tatagagccc cgaatatccg cagtgcgggtt ccatcagcga tgcagaacac gctacaaaat  
 7261 gtgctcattg ccgcaactaa aagaattgc aacgtcacgc agatgcgtga actgccaaca  
 7321 ctggactcag cgacattcaa tgcgaatgc ttgcggaaat atgcgttgc tgacgagtat  
 7381 tgggaggagt tcgctcgaa gccaattagg attaccactg agtttgcac cgcatatgt  
 7441 gctagactga aaggccctaa ggccggcga ctatttgcaaa agacgtataa ttgggtccca  
 7501 ttgcaagaag tgcctatgga tagattcgtc atggacatga aaagagacgt gaaagttaca  
 7561 ccaggcacga aacacacaga agaaagaccg aaagtacaag tgatacaagc cgacgaaacc  
 7621 ctggcgactg cttactttagt cgggattcac cgggaaattag tgcgtaggct tacggccgtc  
 7681 ttgcttccaa acattcacac gcttttgac atgtcggcgg aggatttga tgcaatcata  
 7741 gcagaacact tcaagcaagg cgaccggta ctggagacgg atatgcattt attcgacaaa  
 7801 agccaagacg acgctatggc gttaaccggc ctgatgatct tggaggaccc ggggtgtggat  
 7861 caaccactac tcgacttgcgat cgagtgcgc tttggagaaa tatcatccac ccatctaccc  
 7921 acgggtactc gtttaaatt cggggcgatg atgaaatccg gaatgttccct cacactttt  
 7981 gtcaacacag tttgaatgt cgttatcgcc agcagagttc tagaagagcgc gcttaaaac  
 8041 tccagatgtg cagcggtcat tggcgacgc aacatcatac atggagtagt atctgacaaa  
 8101 gaaatggctg agaggtgcgc cacctggctc aacatggagg ttaagatcat cgacgcagtc  
 8161 atcggtgaga gaccaccta ctctcgccg ggatttatct tgcaagattc gtttacttcc  
 8221 acagcgtgcc gcgtggcggg tccccgtaaa aggctgttta agttgggtaa accgctccca  
 8281 gccgacgacg agcaagacga agacagaaga cgcgcctgc tagatgaaac aaaggcgtgg  
 8341 ttttagatgtg gtataacagg cactttgcgat gtggccgtga cgaccggta tgaggttagac  
 8401 aatattacac ctgtcctact ggcattgaga acttttgcgg agagcaaaag agcattccaa  
 8461 gccatcagag gggaaataaaa gcatctctac qgtggctcta aatagtcaac atagtacatt  
 8521 tcatctgact aatactacaa caccaccacc tctagagctt gcccacca tggtagccaa  
 8581 gggcgaggag ctgttcaccc gggtggtgcc catcctggc gagctggacg ggcacgtgaa  
 8641 cggccacaag ttcagcgtgt cccggcgagg cgagggcgat gccacctacg gcaagctgac  
 8701 cctgaagttc atctgcacca cccggcaagct gcccgtgccc tggcccaccc tcgtgaccac  
 8761 cctgacccatc ggcgtgcagt gttcagccg ctaccccgac cacatgaagc agcagactt  
 8821 cttcaagtcc gccatgcccc aaggctacgt ccaggagcgc accatcttct tcaaggacga  
 8881 cggcaactac aagaccgcg ccgagggtgaa gttcgagggg gacaccctgg tgaaccgc  
 8941 cgagctgaag ggcacatcgact tcaaggagga cggcaacatc ctggggcaca agctggagta  
 9001 caactacaac agccacaacg tctatcat ggcgcacaag cagaagaacg gcatcaagg  
 9061 gaactcaag atccgcccaca acatcgagg cggcagcgtg cagctcgccg accactacca  
 9121 gcagaaacacc cccatcgccg acggccccgt gctgctgccc gacaaccact acctgagcac  
 9181 ccagtcgccc ctgagcaaaacg accccaaacga gaagcgcgat cacatggtcc tgctggagtt  
 9241 cgtgacccgc gccgggatca ctcacggcat ggacgagctg tacaagtaaa gcccggcgtga  
 9301 gcatgcaggc cttggggcca atgatccgac cagaaaact cgatgtactt ccgaggaact  
 9361 gatgtgcata atgcattcagg ctggtagtattt agatccccgc ttaccgcggg caatata  
 9421 acactaaaaaa ctcgatgtac ttccgaggaa ggcgcgtgca taatgtgcg cagtgtgc  
 9481 acataaccac tatattaacc atttatctag cggacgcggaa aaactcaatg tatttctgag  
 9541 gaagcgtggt gcataatgcc acgcacgcgc tgcataactt ttatttattt ttttatttt  
 9601 caacaaaatt ttgttttaa catttcaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa  
 9661 aaaggaaatt ctcgattaa ttaagggcc gctcgagatg gcacacgtgt tacggttta  
 9721 ccgtcgaccc ttagcttagt cttggcgtaa tcatggcat agctgttcc tgggtgaaat  
 9781 tggtagtccgc tcacaattcc acacaacata cgagccggaa gcataaagtg taaaggctgg  
 9841 ggtgcctaattt ggtgcata actcacattt attgcgttgc gtcactgccc cgcttccag  
 9901 tcggggaaacc tgcgtgcata gctgcattaa tgaatggcc aacgcgcggg gagaggcgg  
 9961 ttgcgttattt ggcgccttc cgcttcctcg ctcactgtact cgctgcgc ggtcggtc  
 10021 ctgcggcgag cggatcgtcgc tcaacttgcgat ggcgttccac agaattcagg  
 10081 gataacgcag gaaagaacat gtgagaaaa ggcgcggaa aggccaggaa cgcgtaaaaag  
 10141 gcccgggttgc tggcggtttt ccataggcgc cggccggcc acgagcatca caaaaatcga  
 10201 cgctcaagtcc agagggtggcg aaaccgcaca ggcgttccac gtttccccc  
 10261 ggaagctccc tcgtgcgtc tcctgttccg accctgcgcg ttaccggata cctgtccgc  
 10321 ttctccctt cggggaaagctt ggcgcgttccatgcgttccact gctgttagtgc tctcgttcc  
 10381 gtgttagtgc ttgcgttccaa gctgggtgtt gtgcacgcac ccccccgttca gcccggcc  
 10441 tgccgttat cccgttaacta tcgttgcgttgc tccaaaccggg taagacacga cttatcgcc  
 10501 ctggcagcag ccactggtaa caggattgc agagcgcggg atgttaggcgg tgctacagag  
 10561 ttcttgcgttgc ggtggccata ctacggctac actagaagaa cgtttagtgc tatctgcgc  
 10621 ctgcgttccaa cggaaaaga gttggtagtgc ttgcgttccgg caaacaacc  
 10681 accgcgttccaa gccgtgggtt ttgttgc aagcgcgcgaa ttacgcgcg aaaaaaaaaa  
 10741 tctcaagaag atcccttgcgttccaa cttttctacg gggctgcgttca ctcagtgaa cggaaaactca

10801 cguttaaggga ttttggtcat gagattatca aaaaggatct tcacctagat cctttaaat  
10861 taaaaatgaa gttttaaatac aatctaaagt atatatgagt aaacttggtc tgacagttac  
10921 caatgcttaa tcagtgggg acctatctca gcgatctgtc tatttcgttc atccatagtt  
10981 gcctgactcc ccgtcggtta gataactacg atacgggagg gcttaccatc tggccccagt  
11041 gctgcaatga taccggcgaga cccacgctca ccggctccag atttacgac aataaaccag  
11101 ccagccggaa gggccgagcg cagaagtggt cctgcaactt tatccgcctc catccagtct  
11161 attaattgtt gccgggaagc tagagaagt agttcgccag ttaatagtt gcgcaacgtt  
11221 gttggcattt ctacaggcat cgtgggtgtca cgctcgctgt ttggatggc ttcattcagc  
11281 tccgggttccc aacgatcaag gcgaggtaa tgatccccca tggatggcaaa aaaagcggtt  
11341 agctccctcg gtcctccgtat cggttcaga agtaagttgg ccgcagtgtt atcactcatg  
11401 gttatggcag cactgcataa ttctttact gtcatgccat ccgtaaagatg cttttctgtg  
11461 actgggtgagt actcaaccaa gtcattctga gaatagtgtt tgccggcgacc gagttgctct  
11521 tgccggcggtt caatacggga taataccggc ccacatagca gaacttaaa agtgctcatc  
11581 attggaaaac gtttttcggg gcgaaaactc tcaaggatct taccgtgtt gagatccagt  
11641 tcgatgtaac ccactcggtc acccaactga ttctcagcat cttttacttt caccagcggtt  
11701 tctgggtgag caaaaacagg aaggcaaaaat gccgcaaaaaa agggataaag ggcgacacgg  
11761 aaatgttgaa tactcataact ctccctttt caatattttt gaagcattta tcagggttat  
11821 tgtctcatga gcggtacat atttgaatgt atttagaaaa ataaacaaat aggggttccg  
11881 cgacatttc cccgaaaaagt ggcacactgac gtc

//

## CLAIMS

1. A replication defective virus like particle (VLP) comprising:
  - a. an alphavirus replicon isolated from a Sindbis virus or Venezuelan equine encephalitis virus comprising a recombinant polynucleotide comprising a sequence encoding Sindbis virus or Venezuelan equine encephalitis virus nonstructural proteins (NSP) NSP1, NSP2, NSP3, and NSP4; and a retroviral packaging signal isolated from Rous sarcoma virus,
  - b. a retroviral gag protein encoded by a polynucleotide comprising a genomic sequence of a Rous sarcoma virus, and
  - c. a fusogenic envelope protein,  
wherein the VLP does not contain an alphavirus structural protein gene.
2. The VLP of claim 1, wherein the fusogenic envelope protein is encoded by a polynucleotide comprising a genomic sequence encoding an envelope protein selected from the group consisting of haemagglutinin, Rous sarcoma virus fusion protein, an E protein of tick borne encephalitis virus and dengue fever virus, the E1 protein of Semliki Forest virus, baculovirus envelope glycoprotein (gp64), Vesicular stomatitis (Indiana) virus-EnvA (VSV-EnvA), and Vesicular stomatitis (Indiana) virus-G (VSV-G) protein.
3. The VLP of claim 1 or 2, wherein the VLP is not cytopathic to a eukaryotic cell.
4. The VLP of any one of claims 1 to 3, wherein the alphavirus replicon comprises a promoter of a virus RNA-dependent RNA polymerase, wherein said promoter is linked to the recombinant polynucleotide.
5. The VLP of any one of claims 1 to 4, wherein the recombinant polynucleotide encodes an antisense RNA, that knocks down expression of a gene in a eukaryotic cell.
6. The VLP of any one of claims 1 to 5, wherein the recombinant polynucleotide encodes a short hairpin RNA or small hairpin RNA (shRNA) or a microRNA (miRNA), wherein the shRNA or miRNA knocks down expression of a gene in a eukaryotic cell.

7. The VLP of any one of claims 1 to 6, wherein the VLP does not comprise or express a retroviral pol gene.
8. The VLP of any one of claims 1 to 7, wherein the recombinant polynucleotide comprises a sequence that encodes for HLA-DR1 (MHC II) and CD80.
9. The VLP of claim 8, wherein the replicon is from Venezuelan equine encephalitis virus and the HLA-DR1 is under the control of one subgenomic promoter and CD80 is under control of a different subgenomic promoter
10. A method of producing the VLP of any one of claims 1 to 9 comprising:
  - a. co-transforming a eukaryotic cell with:
    - i. a first vector comprising a polynucleotide sequence encoding the alphavirus replicon,
    - ii. a second vector comprising a polynucleotide comprising the genomic sequence of the Rous sarcoma virus encoding the gag protein, and
    - iii. a third vector comprising a polynucleotide sequence encoding the fusogenic envelope protein;
  - wherein none of vectors (i)-(iii) contain any alphavirus structural genes;
  - b. culturing the co-transformed cell under conditions suitable to cause each vector to produce its encoded product, thereby producing the VLP; and
  - c. isolating the VLP from the cell;

wherein the cell does not contain any alphavirus structural protein genes.
11. A compound comprising the VLP of any one of claims 1 to 9, for use as a medicament.
12. The use of the VLP of any one of claims 1 to 9, in the preparation of a pharmaceutical composition for treating a disease or disorder in a subject in need thereof.
13. A method of gene therapy in a subject in need thereof comprising administering the VLP of any one of claims 1 to 9.

14. A pharmaceutical composition comprising the VLP of any one of claims 1 to 9 and a pharmaceutically acceptable carrier or excipient.

**THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF  
HEALTH AND HUMAN SERVICES**

WATERMARK INTELLECTUAL PROPERTY PTY LTD

P39648AU00

FIG. 1A





FIG. 1B



FIG. 1C



2/12

+





FIG. 2

+

3/12

+



4/12

+




FIG. 4A



FIG. 4B




FIG. 4C

+

FIG. 5B



FIG. 5A



FIG. 5D





FIG. 5C






FIG. 6A






FIG. 6B

7/12



8/12




FIG. 8

9/12

+




FIG. 9A



FIG. 9B




FIG. 9C




FIG. 9D




FIG. 9E




FIG. 9F






FIG. 9G

+

10/12

+



11/12

+




FIG. 11

+

12/12

+




FIG. 12

+